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Original Papers
Regulation of the Mouse Treacher Collins Syndrome Homolog
(Tcof1) Promoter Through Differential Repression
of Constitutive Expression
Kathryn H. Shows and Rita Shiang
Treacher Collins syndrome is an autosomal-dominant mandibulofacial dysostosis caused by haploinsufficiency of
the TCOF1 gene product treacle. Mouse Tcof1 protein is approximately 61% identical and 71% similar to treacle,
and heterozygous knockout of Tcof1 causes craniofacial malformation. Tcof1 expression is high in developing
neural crest, but much lower in other tissues. To investigate this dual regulation, highly conserved regions
upstream of TCOF1 homologs were tested through deletion and mutation reporter assays, and conserved pre-
dicted transcription factor binding sites were assessed through chromatin binding studies. Assayswere performed
in mouse P19 embryonic carcinoma cells and in HEK293 cells to determine differential activation in cell types at
different stages of differentiation. Binding of Cebpb, Zfp161, and Sp1 transcription factors was specific to the Tcof1
regulatory region in P19 cells. The Zfp161 binding site demonstrated P19 cell–specific repression, while the
Sp1=Sp3 candidate site demonstrated HEK293 cell–specific activation. Moreover, presence of c-myb and Zfp161
transcripts was specific to P19 cells. A minimal promoter fragment from 253 to +43 bp directs constitutive
expression in both cell types, and dual regulation of Tcof1 appears to be through differential repression of this
minimal promoter. The CpG island at the transcription start site remains unmethylated in P19 cells, 11.5 dpc
mouse embryonic tissue, and adult mouse ear, which supports constitutive activation of the Tcof1 promoter.
Introduction
Treacher Collins syndrome (TCS) is an autosomal-dominant disorder of craniofacial development with
highly variable expressivity. The phenotype is limited to tis-
sues derived from the neural crest, specifically the first and
second branchial arch derivatives. TCS is characterized by
micrognathia, sometimes with secondary tracheal insuffi-
ciency, middle ear ossiclemalformation oftenwith conductive
hearing loss with or without absence or malformation of the
outer ear, hypoplastic zygomatic arches, flattened maxilla,
downslanting palpebral fissures with coloboma of the lower
eyelid, and sometimes cleft palate. In addition, there is no
mental deficiency associated with TCS (OMIM accession no.
154500; Marsh and Dixon, 2000; Marszalek et al., 2002).
The human TCOF1 gene is localized to chromosome 5q32
and consists of 28 exons, some of which are alternatively
spliced across and among species, and encodes the nucleolar
phosphoprotein treacle (The Treacher Collins Syndrome
CollaborativeGroup, 1996;Dixon et al., 1997a, 2006; Isaac et al.,
2000; So et al., 2004; Splendore et al., 2005; Shows et al., 2006).
TCS has been associated with several nonsense mutations
within the TCOF1 gene, as well as missense mutations within
conserved domains of the coding region (Gladwin et al., 1996;
Edwards et al., 1997; Wise et al., 1997; Splendore et al., 2000,
2002; Marszalek et al., 2003). Nonsense mutations in TCOF1
likely cause haploinsufficiency of full-length treacle, either
through nonsense-mediated mRNA decay (NMD) or through
protein truncation that eliminates nuclear and nucleolar lo-
calization signals so that the protein is mislocalized (Marsh
et al., 1998; Winokur and Shiang, 1998; Frischmeyer et al.,
2002). However, TCS families with linkage to the 5q32 locus
without mutations in the TCOF1 coding region could have
defective expression of TCOF1 that could cause hap-
loinsufficiency of transcript and result in TCS (unpublished
data; Splendore et al., 2000). Understanding normal regulation
of TCOF1 enables screening for abnormal regulation. More-
over, factors that regulate TCOF1 may contribute to the phe-
notypic heterogeneity inherent in TCS, including variable
expressivity.
The mouse Tcof1 gene is well conserved and has 71.1%
similarity at the amino acid level to its human counterpart
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TCOF1 (Dixon et al., 1997b; Paznekas et al., 1997). Hap-
loinsufficiency of Tcof1 in heterozygous knockout mice causes
a TCS-like phenotype, although defects vary from mild to
severe depending on the mouse strain, thus modifying factors
influence the heterogeneous phenotype (Dixon and Dixon,
2004; Teber et al., 2004). Tcof1 is expressed at high levels
ubiquitously until E6, when the high expression becomes
tissue-restricted to the developing neural crest, with highest
expression at E8.5 as cells begin to migrate (unpublished data;
Dixon et al., 1997b, 2000; Paznekas et al., 1997). After E11,
expression then decreases and continues unrestricted in var-
ious tissues (unpublished data; Dixon et al., 1997b, 2000;
Paznekas et al., 1997). Tcof1 is thus regulated both develop-
mentally and tissue specifically in mice.
Tissue-restricted high levels of treacle are likely involved in
ribosome biogenesis during survival and=or proliferation of
developing neural crest cells to ensure proper development of
neural crest-derived structures (Winokur and Shiang, 1998;
Dixon et al., 2000, 2006; Hayano et al., 2003; Valdez et al., 2004;
Gonzalez et al., 2005). However, low constitutive expression
of Tcof1 suggests the necessity for Tcof1 in other tissues under
a different regulatory scheme, as evidenced in the embryonic
lethal phenotype of Tcof1= homozygous knockout mice
(Dixon et al., 1997b). Investigation of both high tissue-
restricted and low unrestricted expression of Tcof1will help to
elucidate the need for Tcof1 in different tissues. In this study
we utilize mouse Tcof1 to investigate regulation, because it
models human TCOF1 regulation. Furthermore, Tcof1 and its
upstream region show remarkable homology across many
different mammal species, so that it can be used to study
species-specific effects in vertebrate craniofacial development.
In this paper we identify sequences upstream of Tcof1 that
are highly conserved across mammalian species, and then
determine the regulatory region and minimal promoter for
constitutive expression of Tcof1 through deletion analysis of
conserved sequences. We then identify candidate transcrip-
tion factor binding sites within the regulatory region, and
assess the specificity of these sites through mutation analysis
and in vivo transcription factor binding studies. We then in-
vestigate cell-specific differences in Tcof1 regulation by com-
paring expression in mouse P19 embryonic carcinoma cells to
HEK293 cells, and determine differential expression of can-
didate transcription factor transcripts in these cell lines. Fi-
nally, we investigate the role of CpGdinucleotidemethylation
in the GC-rich minimal promoter to further support consti-
tutive activation of Tcof1.
Materials and Methods
Bioinformatics of upstream Tcof1 homology
To investigate mammalian sequence conservation of the
TCOF1 regulatory region, genomic sequences including sev-
eral kilobases (kb) upstream of the transcription start site
(TSS) for human (GenBank accession no. AY460334), mouse
(GenBank accession no. NM_011552), chimpanzee (GenBank
accession no. XM_527074), rat (GenBank accession no.
AA875103), dog (GenBank accession no.NM_001003057), and
rhesusmacaque (GenBankaccessionno.NM_001039952)were
compared using the NCBI BLAST BL2seq tool for sequence
identities (Dixon et al., 1997a, 1997b; Tatusova and Madden,
1999; Haworth et al., 2001; Kent et al., 2002; Shows et al., 2006).
Reverse transcription PCR of neural crest precursor
marker transcripts
To ensure that the P19 cell line contained appropriate
marker transcripts, total RNA was extracted from P19 cell
pellets using the Trizol method for tissue culture cells as re-
commended by the manufacturer (Invitrogen, Carlsbad, CA).
Total RNA was treated with 20 units of RQ1 DNase in 1RQ1
buffer to remove DNA contamination as recommended by the
manufacturer (Promega,Madison,WI). First strand cDNAwas
generated using approximately 500ng DNase-treated total
RNA with 5ng=mL both oligo dT and random primers, and
0.5mM dNTPs then heated to 658C for 5min and quick-cooled
on ice; to this was added 1 First-strand buffer, 0.01M DTT,
and 40units RNase inhibitor (Promega) and incubated at 378C
for 2min; then to this was added 200units Moloney-murine
leukemia virus reverse transcriptase (M-MLV-RT) and was
incubated at 378C for 50min with a final incubation at
708C for 15min. Transcript-specific primers used in reverse
transcription (RT)-PCR are given 50 to 30: GAPDH RT-F actt
caacagcgacacccactc and GAPDH RT-R ccctgttgctgtagccaaattc;
mAP-2 RT-F caatgagcaagtggcaagaa and mAP-2 RT-R agggcctc
ggtgagatagtt; mFoxd3 RT-F tcttacatcgcgctcatcac and mFoxd3
RT-R tcttgacgaagcagtcgttg; mMsx1 RT-F ctctcggccatttctcagtc
and mMsx1 RT-R tactgcttctggcggaactt; mSlug RT-F gcactgtga
tgcccagtcta and mSlug RT-R cagtgagggcaagagaaagg; mSnail1
RT-F cttgtgtctgcacgacctgt and mSnail1 RT-R cttcacatccgagt
gggttt; mTwist RT-F ccccactttttgacgaagaa and mTwist RT-R
cagtttgatcccagcgtttt; and mWnt-1 RT-F acagcaaccacagtcgtcag
and mWnt-1 RT-R gaatccgtcaacaggttcgt. Standard PCR was
accomplished in 12.5mL reactions in 1PCR buffer (CLP, San
Diego, CA), 0.5mM dNTPs, 3.125 pmol each primer, 0.25units
Taq polymerase (GeneChoice), and 1.5mL of a 1:10 dilution of
cDNA. Cycling conditionswere denaturation at 948C for 2min;
then 22 cycles of 948C for 30 s, 608C for 30 s, and 728C for 30 s;
and then extension at 728C for 7min.
Cloning of Tcof1 promoter regions
Eighteen clones represent serial deletions of seven highly
conserved sequences within the 2.1 kb full-length upstream
fragment comprising construct 1C (Fig. 1A). Control plasmids
used were pGL3-control encoding the recombinant firefly
luciferase gene under control of the strong SV40 promoter;
negative control pGL3-basic, containing no promoter; and
pCMV-bgal, containing the bacterial b-galactosidase gene
under control of the strong CMV promoter (Promega).
Cloning of the upstream region 1751 to þ1000 bp of Tcof1
was accomplished using restriction endonuclease digestion
by KpnI and XhoI of the previously cloned mouse genomic
Tcof1 (clone pm7c2HSI), to generate a 2.8 kb fragment that
was inserted into the pBluescript II=SKþ(pBSSKþ) vector
(Stratagene, La Jolla, CA). After sequence verification, part of
the upstream region in pBSSKþ was then released with KpnI
and NheI and inserted into the pGL3-basic vector (Promega)
to create clone 1A. Clone 1C was created by inserting a 2.8 kb
upstream fragment from KpnI to NcoI into pGL3-basic. The
clone 1B was created by inserting the KpnI to SmaI fragment
from 1C into pGL3-basic. The full-length clone 1C was then
digested with various restriction endonucleases, and frag-
ments were blunt-end subcloned into SmaI-digested and de-
phosphorylated pGL3-basic: for clone 2BNdeI=SmaI digestion
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with Klenow fill-in of the 50 end; for clone 3B SspI=SmaI di-
gestion; for clone 4B HincII=SmaI digestion; for clone 5B
SfoI=SmaI digestion; and for clone 6B PvuII=SmaI digestion
(New England Biolabs, Ipswich, MA) (Fig. 1A). For clones 4A,
5A, and 6A fragments were released with NheI digestion and
inserted into theNheI site of pGL3-basic; for clones 2A and 3A
fragments were released with SpeI and NcoI to replace a
520 bp fragment with the 458 bp SpeI to NcoI fragment from
1A (New England Biolabs). Clones 2C, 3C, 4C, 5C, and 6C
were created by digestion with KpnI and SmaI to replace the
KpnI to SmaI fragment in 1C. Digest products were separated
through 0.8% agarose in 1TAE for gel extraction with Freeze
N’ Squeeze columns (Bio-Rad, Hercules, CA). Ligations were
performed using 200 units of T4 DNA ligase (New England
Biolabs) in 1 ligation buffer (50mM Tris, pH 7.5; 10mM
MgCl2; 5% PEG 8000; 1mM ATP; 1mM DTT), with approxi-
mately 20 ng vector and approximately 50 ng insert, and in-
cubated overnight at 168C or for 1 h at room temperature.
After sequence verification of the entire insert, plasmid DNA
was purified using the Qiagen Qiafilter midi-prep kit as re-
commended by the manufacturer (Valencia, CA).
Tissue culture and transient transfection
Mouse P19 cells were grown in Modified Eagle’s Medium
(MEM-a) supplemented with 7.5% bovine calf serum, 2.5%
fetal bovine serum (FBS), and 50 mg=mL gentamicin (Invitro-
gen). Cells were passaged once at approximately 50–65%
confluency, then plated for transfections at a density of 1104
cells per well in a six-well plate. Cloned reporter plasmids
were transiently transfected in triplicate into P19 cells using
Lipofectamine 2000 reagent (Invitrogen) following the man-
ufacturer’s protocol. Cells were cotransfected with pCMV-b-
gal in order to assess transfection efficiency and normalize
data points. Transfection medium was replaced after 4 h with
incubation at 378C in 5% CO2. Transfections were incubated
for 24 h prior to cell lysis.
Expression analysis
Cells were lysed in Tropix 1 reporter lysis buffer and as-
sayed using the Promega Luciferase Assay System and the
Tropix Galacto-Star system (Applied Biosystems, Foster City,
CA) as recommended by the manufacturer. Assays were read
in a Wallac Victor2 1420 Multilabel Counter plate reader
(PerkinElmer, Waltham, MA). The ratio of luciferase to b-gal
expression was calculated for each well and normalized by
the ratio of luciferase to b-gal expression for pGL3-basic.
Each normalized ratio was divided by the normalized pGL3-
control ratio to achieve the fold-of-control value, and standard
deviations were calculated for each triplicate mean. Means
were compared for significance using a two-tailed paired or
non-paired homoscedastic or heteroscedastic Student’s t-test,
where appropriate.
Identification of candidate transcription
factor binding sites
Regions of homology were then examined for putative
transcription factor binding sites using the Transcription
Element String Search (TESS) program, which uses the
TRANSFAC database (Schug, 2003). Sites identical and near-
identical in all species in sequence and approximate distance
from the TSSwere selected for further study, including from 50
to 30 LVa, Ikaros-1, c-myb, CCAAT, Zfp161, Sp1=Sp3, and
AP2a putative binding sites (Fig. 2).
Mutation of candidate transcription factor
binding sites
Mutations of putative binding sites in the Tcof1 promoter
were generated using the oligonucleotide-directed GeneE-
ditor II mutagenesis system (Promega) as recommended by
the manufacturer. Mutation oligos are given in Table 1. Re-
striction positive clones were sequence verified to contain the
mutation. Mutation clones were transfected, and expression
was analyzed exactly as above.
FIG. 1. Deletion analysis of the mouse Tcof1 regulatory
region. Deletions from the 50 and 30 ends of the regulatory
region show different effects on expression of the reporter
gene luciferase in vitro. (A) Schematic representation of the
inserts used in deletion clones is shown. Six different 50 ends
are labeled 1–6, while three different 30 ends are labeled a, b,
and c, and position relative to the TSS (þ1) is indicated be-
low. Fragments were inserted into pGL3-basic, and are
named using the combination of the numbered 50 end and
the lettered 30 end. Corresponding restriction sites are 1,
KpnI; 2, NdeI; 3, SspI; 4, HincII; 5, HaeII; 6, PvuII; a, NheI; b,
SmaI; and c, NcoI. Vertical arrows indicate peaks of areas
of conservation among vertebrates. A bent arrow indicates
the initiator ATG codon, and the gray box indicates exon 1.
(B) Transient transfection luciferase expression analysis of
deletion clones in P19 mouse embryonic carcinoma cells.
Transfections were performed in triplicate and are shown as
a fold-of-control value with standard deviations. Compar-
isons of results are pairwise, with each construct compared
to the immediate longer construct to assess specific effects of
deletion. Bracketed groups assess significance of 30 deletions
by comparing pairwise 50 deletions within the group and
testing significance of the group. Significance of comparisons
is determined using the appropriate Student’s t-test with
*p< 0.01, **p< 0.005, or ***p< 0.001.
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Differential expression of Tcof1 promoter constructs
To investigate differential expression between cell types,
deletion andmutation assayswere performed inHEK293 cells
that were grown in Dulbecco’s modified Eagle’s medium
supplemented with 10% FBS and 1% penicillin=streptomycin
(Invitrogen). Cells were passaged twice at approximately 85–
90% confluency, then plated for transfections at a density of
1106 cells per well in a six-well plate. Cloned reporter plas-
mids were transiently transfected in triplicate into HEK293 -
cells exactly as above for P19 cells. Transfections were
incubated at 378C in 5% CO2 for 48 h prior to cell lysis. Ex-
pression was analyzed exactly as above for P19 cells.
Differential expression of candidate
transcription factor transcripts
To determine differential transcription of candidate tran-
scription factors, semi-quantitative RT-PCR of candidate
transcripts was performed and primers are given 50 to 30:
GAPDH RT F=GAPDH RT R; mAP-2 RT-F=mAP-2 RT-R;
Cebpa RT-F ttacaacaggccaggtttcc and Cebpa RT-R ctctggga
tggatcgattgt; Cebpb RT-F caagctgagcgacgagtaca and Cebpb
RT-R cagctgctccaccttcttct; Cebpd RT-F atcgctgcagcttcctatgt
and Cebpd RT-R agtcatgctttcccgtgttc; Cebpz RT-F atccttctg
tggcccttttt and Cebpz RT-R ttgggttgcatcacaacact; c-myb RT-F
gctgaagaagctggtggaac and c-myb RT-R caacgcttcggaccatattt;
Zfp161 RT-F agctcaggggagcttttgtt and Zfp161 RT-R cagggg
caagccagatataa; Ik-1 RT-F cacaacgagatggcagaaga and Ik-1 RT-
R cccaggtagttgatggcatt; and Sp1 RT-F agcgaccaagatcactccat
and Sp1 RT-R tgggtgactcaattctgctg. Transcripts were isolated
and cDNA was synthesized as above. Standard PCR was
accomplished as above.
Chromatin immunoprecipitation
P19 cells were maintained as above until 50–60% con-
fluency, and then scraped into cold 1 PBS diluted to ap-
proximately 500 cells per 1mL. Native protein–chromatin
complexes were cross-linked in 1% formaldehyde for 17min
at room temperature, and then the reaction was quenched
using 0.125M glycine. Cell lysis and immunoprecipita-
tion (IP) was then performed according to the manufactur-
er’s recommendations (Santa Cruz Biotechnologies, Santa
Cruz, CA) using EDTA-free protease inhibitor cocktail
(Roche, Indianapolis, IN). Samples were sonicated to frag-
ment chromatin using a Heat Systems Ultrasonics Cell Dis-
ruptor W-220F (Misonix, Farmingdale, NY) set at output 1,
with 10 rounds of 151-s pulses at 30-s intervals on ice.
Protein concentration of supernatant was determined by
FIG. 2. Conserved putative transcription factor binding sites within the Tcof1 regulatory region. Consensus sites for con-
served predicted transcription factor binding sites are given on the top row, with species names in the left column. Consensus
binding site direction is shown as forward (þ) or reverse () relative to the Tcof1 open reading frame. Nonconsensus
nucleotides are in lower case and bold type, while consensus nucleotides are in upper case. The position indicated at the
bottom is for the mouse Tcof1 sequence.
Table 1. Site-Directed Mutation Oligonucleotides
Oligo sequence
Restriction site used
for screeningCandidate trans-factor Consensus sequence
c-myb CGCGTGCTAGCCCA t g gGTTTGCTTTGTTTCTCa NcoI
CGCGTGCTAGCCCAACTGTTTGCTTTGTTTCTC
CCAAT GACACGCCTTGGAGCCtATaGCAGAGCTAGTTAG SfcI
GACACGCCTTGGAGCCAATGGCAGAGCTAGTTAG
Zfp161 CCCAGCGTGCC a t a t GGCCCGGTGACGCG NdeI
CCCAGCGTGCCGCGCGGCCCGGTGACGCG
Sp1 GAGCAGTAGCCCGCTCCC a g t CCGGGAGACCTGGC SmaIb
GAGCAGTAGCCCGCTCCCCTCCCGGGAGACCTGGC
AP2a GACTTATAGCCACTTCCt g a GGCTCAGTTTCCCCATG c
GACTTATAGCCACTTCCCAGGGCTCAGTTTCCCCATG
The oligonucleotide sequence is shown with the wildtype sequence underneath for comparison. The conserved cis-binding site is shown in
bold type, with the nucleotide changes in lowercase and underlined.
aSequence is specific to the plasmid with insert.
bSite is present in wildtype sequence.
cMutation was identified through sequencing.
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modified protein assay (Bio-Rad), and approximately 500mg
total protein was used per IP. Chromatin samples were pre-
cleared with 50 mL Protein A=G PLUS-Agarose (Santa Cruz
Biotechnologies). Either 1.5 or 3mg antibody [AP-2a (3B5), c-
myb (H-141), Sp1 (PEP 2), Sp3 (D-20), C=EBPb (H-7), or
ZNF161 (ZNF5J141) (Santa Cruz)] or no antibody control
was used for IP. Free chromatin was extracted using phenol–
chloroform procedure and quantitated using Picogreen
(Molecular Probes [Invitrogen]) reagent as recommended by
the manufacturer.
Primers upstream of mouse Tcof1 TSS surrounding the
conserved c-myb binding site are 50 to 30 mChIP c-myb F
(ctgctgtctttggggct) and mChIP c-myb R (tatgtttggatcgcgcct);
surrounding the CCAAT binding site are ChIP mC=EBPb
F (atgaatactcggaagc) and ChIP mC=EBPb R (ccacgaaggctaa
cta); and surrounding the Zfp161 site and CpG island are
MTcof1 Met 1F (actccagctgcaagactacac) and MTcof1 Met 1R
(cgctctgctcctttacttcc). Primers surrounding the Sp1=Sp3 and
AP2a conserved sites are mChIP Sp1=3 F (cgggaagtaaaggag
cagag) and mChIP Sp1=3 R (cgggaattacaaagctgcac). PCR was
accomplished as described previously, with annealing tem-
perature of 558C, 568C, and 608C, respectively, for 40 cycles of
amplification.
MethylScreen analysis of GC-rich promoter region
The MethylScreen assay was adapted for use in the mouse
Tcof1 gene (Holemon et al., 2007). Primers MTcof1 Met 1F and
MTcof1 Met 1R (given above) amplify the 252 bp predicted
CpG island surrounding the TSS and encompassing 6 HhaI
sites and 15 McrBC sites. Genomic DNA was extracted from
P19 cell pellets or from mouse tissue using the Wizard
Genomic DNA purification kit according to the manufactur-
er’s recommendations (Promega). Control methylated DNA
was generated by subjecting P19 genomic DNA to methyla-
tion by HhaI methylase or SssI methylase according to the
manufacturer’s recommendations (New England Biolabs).
Both control methylated and untreated P19 and mouse tissue
genomic DNA samples were then subjected to digestion
using: (1) methyl-sensitive HhaI, (2) methyl-dependent
McrBC, (3) both HhaI andMcrBC, or (4) glycerol only. PCR of
digest products was accomplished as above with annealing
temperature at 568C for 30 cycles. Patterns of amplification
were compared for differences.
Results
Identification of conserved regions upstream of Tcof1
The upstream region of mouse Tcof1 is homologous to the
human TCOF1 upstream region, especially in small (20–200
bp) nearly identical (80–100% identity) segments. There are
four main areas conserved between mouse and human, spe-
cifically the proximal upstream region at approximately þ1
bp to 1 kb and enhancer-like regions farther upstream at
approximately –3, –4.5, and –6.5 kb. These regions are located
at least 50 kb from the closest known transcript found up-
stream of Tcof1 (Kent et al., 2002). Small regions of near exact
homology were identified surrounding peaks of conservation
at the TSS and at þ350 bp in intron 1, and then at approxi-
mately25,70,800,1100, and1700 bp upstream of the
TSS, as indicated by vertical arrows in Figure 1A. We chose to
investigate the proximal 2 kb region because of the high de-
gree of homology among different species.
Determination of Tcof1 promoter regulatory regions
in P19 cells
Mouse P19 embryonic carcinoma cells are developmentally
pluripotent, derived from a 7.5 dpc embryo, with the potential
to differentiate into all three germ layers, including neu-
roectoderm from which the neural crest arises (McBurney,
1993). As mentioned previously, Tcof1 is expressed at very
high unrestricted levels in early mouse embryo, and also at
high levels in P19 cells (Mogass et al., 2004). To ensure that the
P19 cell line is appropriate for this study, we confirmed ex-
pression of AP2a, Foxd3,Msx1, Slug, Snail1, Twist, andWnt-1
genes that are involved in early neuroectoderm and neural
crest cell survival using RT-PCR analysis (Borchers et al.,
2001). We were able to readily detect these marker transcripts
using mRNA-specific primers; thus, the P19 cell line remains
undifferentiated with pluripotency (data not shown).
Several deletion clones were constructed to specifically test
highly conserved near-identical sequences upstream of Tcof1
that were identified through BLAST analysis, and deletions
from the 50 and 30 ends of a 2.1 kb upstream region are re-
presented schematically in Figure 1A. Results from transient
transfections in P19 cells are shown in Figure 1B. Comparisons
are pairwise, with each construct compared to the immediate
longer construct to assess specific effects of deletion. Com-
parisons are significant at p< 0.001 unless otherwise noted,
and most significant ( p< 0.001) results are given in Table 2.
Deletion of 1751 to 942 bp consistently shows an in-
crease in expression (2C vs. 1C, 2B vs. 1B, and 2A vs. 1A),
demonstrating that this region encompasses a repressor. De-
letion of 829 to 453 bp shows an increase in expression
with the þ43 bp end (4A vs. 3A), and further deletion from
453 to 253 bp also shows an increase in expression with
þ256 and þ43 bp ends (5B vs. 4B, 5A vs. 4A, p< 0.005), sug-
gesting that there are repressor elements that are context
dependent. Deletion of the region from þ43 to þ256 bp that
includes exon 1 and part of intron 1 increases expression (A
vs. B, p< 0.005), suggesting a repressor element within the
deleted region. Deletion of the intronic region from þ256 to
þ367 bp significantly increases expression (B vs. C), which
demonstrates a repressor element within the intron. In con-
trast, deletion of 253 to 53 bp significantly decreases ex-
pression (6B vs. 5B, 6A vs. 5A), demonstrating that the deleted
fragment contains the activator element.
In summary, the region that confers greatest expression is
the minimal promoter of Tcof1 from 253 to þ43 bp, or con-
struct 5A. Multiple upstream and intronic sequences then
confer repression on this minimal promoter as shown by the
increase in expression due to deletion of regions 1751 to
942 bp (2), 829 to 453 bp (4), 453 to 253 bp (5), þ43 to
þ256 bp (B), and þ256 to þ367 bp (C).
Identification of candidate transcription
factor binding sites
Using the TESS website, we further investigated the highly
conserved region upstream of TCOF1 to identify putative
transcription factor binding sites. Mammalian (i.e., mouse, rat,
dog, rhesus macaque, chimpanzee, and human) homologs of
TCOF1-2kb upstream sequence contain five upstream and two
intronic candidate transcription factor binding sites that coin-
cide with highly conserved regions utilized in the deletion
analysis with 70–100% identity, although the positions of the
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sites vary slightly among species (Dixon et al., 1997a, 1997b;
Haworth et al., 2001; Schug, 2003; Shows et al., 2006). Other
predicted cis-regulatory sites were identified within the 2kb
sequence, although they are not conserved across all species,
which suggests that species-specific regulation of TCOF1 may
account for species-specific differences in craniofacial skeletons.
The consensus and sequences of the seven highly con-
served sites are shown in Figure 2, with positions shown be-
low for the mouse sequence. The consensus site at 847 bp is
predicted to bind an uncharacterized nuclear factor that ac-
tivates the LVa promoter element in Moloney-Murine Leu-
kemia Virus (M-MLV) and Walleye Dermal Sarcoma Virus
(WDSV) and coincides with the peak of high conservation
seen at 800 bp upstream of the TSS (Speck and Baltimore,
1987; Hronek et al., 2004). The consensus site at 732 bp is in
reverse orientation and is predicted to bind Ikaros factor (Ik-
1), a six-finger zinc-binding protein important for hemato-
poiesis in mice (O’Neill et al., 2000; Lopez et al., 2002). The
consensus site at 454 bp is predicted to bind c-myb factor, a
leucine-zipper oncoprotein required in the neuroectoderm to
mesenchyme transition to form migrating neural crest cells in
chicken, as well as in maxilla and palate development at ap-
proximately E12.5 inmouse (Ness, 2003;Mukhopadhyay et al.,
2004; Karafiat et al., 2005). The consensus site at 117 bp is a
CCAAT box predicted to bind the activator CCAAT binding
factor (mCBF or Cebpz), although many proteins also bind to
the CCAAT core with reduced affinity, including CCAAT=
enhancer-binding protein (Cebp) isoforms a, b, and d (Ramji
and Foka, 2002). The CCAAT box coincides with the peak of
conservation surrounding 70 bp upstream of the TSS. The
consensus site at 29 bp is predicted to bind Zfp161, a zinc-
finger protein that is both an activator and a repressor that
binds to GC-rich sequences and coincides with the peak of
conservation at 25 bp upstream of the TSS (Numoto et al.,
1999). The reverse consensus site at þ245 bp in intron 1 is
predicted to bind the activator Sp1 and=or the repressor Sp3,
homologous factors required in early embryo development
(Lania et al., 1997). The consensus site at þ344 bp is predicted
to bind AP2a, another early embryonic factor shown to be
required for neural crest cell fate determination in Xenopus,
and coincides with the peak of conservation at þ350 bp
downstream of the TSS within intron 1 (Luo et al., 2003).
Functions of cis-regulatory sites
in Tcof1 upstream region
Site-directedmutagenesis was performed on the putative c-
myb, CCAAT, Zfp161, Sp1=Sp3, and AP2a candidate binding
sites to test the function of these highly conserved sequences
in proximity to the TSS. Testing of the Zfp161 site was espe-
cially important because it could not be tested by deletion
analysis. The consensus binding sites were mutated to oblit-
erate binding and to create restriction endonuclease sites for
screening of clones (Table 1). The wildtype constructs 4B
(containing c-myb, CCAAT, and Zfp161 candidate sites), 5B
(containing CCAAT and Zfp161 candidate sites), and 1C (full-
length containing Sp1=Sp3 and AP2a candidate sites) were
used as templates for mutations, and transfection results in
P19 cells are shown in Figure 3. Comparisons are pairwise,
with each mutated construct compared to the equivalent
wildtype construct. Significance of comparisons is at the level
of p< 0.001 unless otherwise noted. A summary of the most
significant ( p< 0.001) results is given in Table 2.
The mutation of the Zfp161 site (Zfp161*5B vs. 5B) yields a
significant increase in expression, demonstrating that this site
participates directly in repression of the Tcof1 gene. Mutation
of the CCAAT site on the 5B template (CCAAT*5B vs. 5B,
p< 0.005) shows a decrease in expression; however, the same
CCAAT mutation on the 4B template shows no change in
expression, suggesting that the CCAAT site may be a cis-
activator in a context-dependent manner. Mutation of the c-
myb site (c-myb*4B vs. 4B, p< 0.01) shows a slight decrease in
expression, suggesting that it may be a cis-activator.
Determination of Tcof1 promoter regulatory
regions in HEK293 cells
The HEK293 human embryonic kidney–transformed cell
line was used as a control cell line to test for differential ex-
pression, since the Tcof1 promoter is known to function at low
levels constitutively in differentiated cells. Deletion constructs
are the same as used for P19 cells. Comparison results for
transfections of deletion constructs in HEK293 cells are shown
in Figure 4A, and most significant ( p< 0.001) results are
summarized in Table 2. Results are significant at p< 0.001
unless otherwise noted.
Table 2. Summary of Results for Analysis of the Mouse Tcof 1 Regulatory Region
P19 cells HEK293 cells
Deletion Conserved site Construct Element Construct Element
Nonspecific
1751 to 942 Unknown 2A, 2B, 2C R 2A, 2C R
þ256 to þ367 AP2a 1B to 6B R 1B to 6B R
P19 specific
829 to 453 Ik-1 4A R — N
253 to 53 CCAAT 6A A 6C R
Mutation Zfp161 5B*Zfp161 R — N
HEK293 specific
453 to 253 c-myb 5B N 5C A
þ43 to þ256 Sp1=Sp3 — N 1A to 6A R
Mutation Sp1=Sp3 — N 1C*Sp1=Sp3 A
Regions are depicted as containing an activator (A), repressor (R), or no effect (N) element. Results are significant at the p< 0.001 level as
assessed by the appropriate Student’s t-test.
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Deletion of 1751 to 942 bp shows an increase in ex-
pression compared to the full-length construct (2C vs. 1C, 2B
vs. 1B, and 2A vs. 1A in Fig. 4A) as in P19 cells, suggesting that
this repressor element is not cell specific. Deletion of 942 to
829 bpwith theþ367 bp end shows a slight increase not seen
in P19 cells (3C vs. 2C, p< 0.01), suggesting a repressor ele-
ment that is cell specific and context dependent. Deletion of
the region from 829 to 453 bp shows no difference in ex-
pression unlike in P19 cells, so that this repressor element is
specific to P19 cells. Deletion of the region 453 to 253 bp
with the þ367 bp end shows a decrease in expression (5C vs.
4C) that is opposite to the increase in P19 cells, so that this
region contains an activator specific to HEK293 cells and=or a
repressor specific to P19 cells. Deletion of the 253 to 53 bp
region causes a significant increase in expression with the
þ367 bp end that is opposite the decrease seen in P19 cells (6C
vs. 5C), suggesting that the repressor may be specific to P19
cells; however, with the þ43 bp end, deletion of this region
causes a slight decrease in expression as seen in P19 cells (6A
vs. 5A, p< 0.01), so that this region shows context-dependent
effects in HEK293 cells. Deletion of the region from þ43 to
þ256 bp containing exon 1 and part of intron 1 (A vs. B) and
deletion of þ256 to þ367 bp (B vs. C) increase expression like
in P19 cells, demonstrating that these fragments contain re-
pressors that are not cell specific.
In summary, the construct showing highest expression in
HEK293 cells is the 253 to þ43 bp construct 5A as in P19
cells, although it is not significantly different from its imme-
diate longer construct. This supports that expression is con-
stitutive in different cell types. Thus, multiple upstream and
intronic repressors have also been demonstrated in HEK293
cells as shown by an increase in expression due to deletion of
the regions 1751 to 942 bp (2), þ256 to þ367 bp (C), and
þ43 toþ256 bp (B) that are not cell specific, and942 to829
bp (3) and253 to53 bp (6) that are specific to HEK293 cells.
This demonstrates differential repression of constitutive acti-
vation between cell types.
To further demonstrate cell-specific effects, mutated con-
structs were also tested in the HEK293 cell line as shown in
Figure 4Bwithmost significant comparison results ( p< 0.001)
FIG. 4. Analysis of cell-specific regulation of Tcof1. (A)
Transient transfection luciferase expression analysis of dele-
tion clones in HEK293 human embryonic kidney trans-
formed cells. Deletion clone constructs are the same as for
P19 cells as in Figure 1A, and results are reported as in Figure
1B. (B) Transient transfection luciferase expression analysis
of site-directed mutation clones in HEK293 cells. Clone
constructs are the same as for P19 cells, and results are re-
ported as in Figure 3.
FIG. 3. Specificity of conserved putative transcription fac-
tor binding sites within the mouse Tcof1 regulatory region.
Site-directed mutation of candidate sites was performed, and
constructs were transiently transfected into the P19 mouse
embryonic carcinoma cell line. The site mutated is indicated
with an asterisk followed by the name of the clone used as
template. Transfections were performed in triplicate, and
results are shown as a fold-of-control value with standard
deviations. Comparisons of results are pairwise, with each
mutated construct compared to the wildtype template. Sig-
nificance of comparisons is determined using the appropriate
Student’s t-test with *p< 0.01, **p< 0.005, or ***p< 0.001.
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summarized in Table 2. Significance is at the level of p< 0.001
unless otherwise noted. Site-directed mutations in Sp1=Sp3
(Sp1=Sp3*1C vs. 1C) andAP2a (AP2a*1Cvs. 1C, p< 0.01) each
shows decreased expression unlike in P19 cells, suggesting
that these elements are activators in HEK293 cells. This is in
contrast to the repressive effect due to deletions of the regions
þ43 to þ256 bp (B) and þ256 to þ367 bp (C), suggesting that
there may be unknown repressors within this region. Muta-
tion of the c-myb site (c-myb*4B vs. 4B, p< 0.005) shows a
decrease in expression, demonstrating that it is an activator of
Tcof1 as in P19 cells. This result is unexpected because there
was no change due to deletion of the 453 to 253 bp region
surrounding the c-myb site in HEK293 cells. Mutation of the
CCAAT site shows no difference in expression unlike in P19
cells. This is expected considering that expression does not
changewhen the CCAAT-containing region253 to53 bp is
deleted in HEK293 cells. Mutation of the Zfp161 site does not
show a significant change in expression unlike in P19 cells.
Thus, the negative regulatory effect of the Zfp161 site appears
to be restricted to P19 cells.
Cell-specific transcription of candidate
transcription factors
To determine whether candidate binding factors may affect
cell-specific expression of constructs, semi-quantitative RT-
PCRwas used to determine the presence of their transcripts in
both P19 and HEK293 cell lines (Fig. 5A and B, respectively)
because antibodies were not available for all factors to de-
termine protein levels. Transcript-specific primers for candi-
dates Cebpa, Cebpb, Cebpd, Cebpz, c-myb, Ik-1, Zfp161, Sp1, and
AP2a are specific for both human and mouse homologous
regions of the genes. In P19 cells, transcripts are readily de-
tectable except for Cebpa, Cebpd, and Ik-1 (Fig. 5A). In HEK293
cells, transcripts are readily detectable except for Cebpa,
Cebpd, c-myb, Ik-1, and Zfp161 (Fig. 5B). Thus, c-myb and
Zfp161 each show cell-specific transcription in P19 cells, but
not in HEK293 cells.
Specific in vivo binding of candidate
transcription factors in P19 cells
Candidate transcription factors for which antibodies were
commercially available (c-myb, Cebpb, Zfp161, Sp1, Sp3, and
AP2a) were tested for binding specificity using chromatin im-
munoprecipitation (ChIP), and results are shown in Figure 6.
Visualization of chromatin shearing demonstrated a range of
average size of about 300–400 bp fragments (data not shown).
Western blot verified presence of these proteins in the P19
cell line (data not shown). Chromatin enrichment above
background was seen for primer set mChIP c-myb F=R sur-
rounding the c-myb binding site using anti-Cebpb, anti-
Zfp161, and anti-Sp1 ChIP (Fig. 6, top) and for primer set ChIP
FIG. 5. Presence of candidate transcription factor tran-
scripts in cell lines. Semi-quantitative reverse transcription
PCR analysis of candidate transcription factors was per-
formed in triplicate, and transcript level was determined as a
ratio of GAPDH transcript level at 22 cycles of PCR. Values
are given with standard deviations for (A) P19 cells and (B)
HEK293 cells. Transcripts not detectable after 40 cycles of
PCR are denoted as n.d.
FIG. 6. Chromatin enrichment of Tcof1 regulatory region.
PCR of enriched chromatin was performed using immuno-
precipitated chromatin samples for (1) no antibody back-
ground control, (2) input chromatin positive control, (3)
anti-c-myb, (4) anti-Cebpb, (5) anti-Zfp161, (6) anti-Sp1, (7)
anti-Sp3, (8) anti-AP2a, and (9) water only. Marker (M)
shows 200 and 300 bp (and 400 bp in middle row) bands.
Amplification shown was performed using a primer set
surrounding the (top) c-myb candidate binding site with a
product size of 219 bp, (middle) CCAAT candidate binding
site with a product size of 222 bp, and (bottom) Zfp161
candidate site with a product size of 252 bp.
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mC=EBPb F=R surrounding the CCAAT binding site using
anti-Zfp161 and anti-Sp3 ChIP (Fig. 6, middle). No chromatin
enrichment was seen for any ChIP with primer sets MTcof1
Met 1F=1R encompassing the CpG island and TSS (Fig. 6,
bottom), or mChIP Sp1=3 F=R encompassing exon 1 and in-
tron 1 (data not shown). Thus, Cebpb, Zfp161, Sp1, and Sp3
factors are associated with chromatin upstream of the TSS
surrounding the c-myb and CCAAT binding sites, but not at
their predicted binding sites.
Mouse Tcof1 promoter is not occupied
by methylated cytosine residues
To support constitutive activation of the Tcof1 promoter,
we performed a modified MethylScreen assay for methylated
cytosine residues within the predicted CpG island at the TSS
of Tcof1, and results are given in Figure 7. Absence of PCR
product indicates complete digestion, while, conversely,
presence of PCR product indicates incomplete digestion. In
P19 cells, E11.5 mouse total embryo, and adult mouse ear,
untreated genomic DNA demonstrates complete digestion
withHhaI andHhaI=McrBC digests, and incomplete digestion
with McrBC and glycerol only. Control methylated P19 ge-
nomic DNA demonstrated predicted but opposite results:
incomplete digestion with HhaI and glycerol only, and com-
plete digestion with McrBC and HhaI=McrBC. Presence of
PCR product forHhaI-methylated DNA digested withMcrBC
indicates incomplete methylation of template, as has been
noted for HhaI methylase previously (New England Biolabs).
Thus, the mouse Tcof1 CpG island within the promoter is not
methylated in P19 cells, E11.5 embryos, or adult mice.
Discussion
The Zfp161 site is a tissue-specific repressor
of Tcof1 expression
Mutation of the Zfp161 site greatly increases expression
above all other constructs in P19 cells, which demonstrates
highest-level activation of the promoter by abolishing re-
pression through this site. Tcof1 displays high-level expres-
sion in the early embryo, so that repression through the
Zfp161 site implies a necessity for tight control of Tcof1 ex-
pression in development. Binding of Zfp161 factor to the Tcof1
regulatory region and transcription of Zfp161 in P19 cells both
support the role of Zfp161 repression on the Tcof1 promoter in
the early embryo. However, Zfp161 does not bind to its pre-
dicted site, so perhaps introducing adenine–thymine pairs by
mutation changes the melting characteristics of the CpG is-
land to alter the integrity of the TSS and further upregulate
activation of this promoter.
On the other hand, activation or repression by Zfp161, a
POK (poxvirus and zinc finger, Kru¨ppel-like) transcription
factor, is context dependent and binding affinity can be
changed through dimerization with self or other Kru¨ppel-like
zinc finger proteins (Numoto et al., 1993; Kaplan and Calame,
1997; Obata et al., 1999; Wang et al., 2005). In fact, Zfp161
associates with chromatin surrounding the c-myb and
CCAAT candidate sites, suggesting that Zfp161 may either
work indirectly in regulation of Tcof1, or bind its own site
weakly because of protein–protein interactions with other
Kru¨ppel-like factors binding the c-myb or CCAAT sites. ChIP
experiments are unlikely to detect weakly binding transcrip-
tion factors, so Zfp161 could still bindweakly to its site, but be
detected as binding at another site as a heterodimer. Zfp161
could then bind its own site strongly in the absence of other
factors, but in P19 cells heterodimerization weakens binding
to its site. In P19 cells elimination of binding throughmutation
of the Zfp161 site in the presence of Zfp161 allows a significant
increase in expression, whereas in HEK293 cells mutation
causes no change in expression in the absence of Zfp161,
which supports the participation of weak Zfp161 binding to
its site in repression of Tcof1 in P19 cells. However, since
Zfp161 is not present in HEK293 cells, Tcof1 is repressed in a
different manner in this cell line.
Zfp161 is localized to subnuclear domains, and is ex-
pressed in various adult tissues (Numoto et al., 1993; Sugiura
et al., 1997). It is unknown if Zfp161 is expressed in developing
neural crest, although in E10.5 mouse it is expressed in the
core of branchial arches one and two, overlapping Tcof1 ex-
pression at this time point (unpublished data; Dixon et al.,
1997b, 2000; Paznekas et al., 1997; Gray et al., 2004). Ectopic
expression of Zfp161 has been shown to suppress prolifera-
tion in mouse cell lines, causing a slow-growth phenotype
(Kaplan and Calame, 1997). Zfp161 may then be required to
attenuate expression of Tcof1 to control proliferation through
weak binding as the neural crest expands.
The CCAAT site is a tissue-specific activator
of Tcof1 expression
The minimal promoter of mouse Tcof1 is shown to be a 296
bp fragment from253 toþ43 bp that contains the conserved
CCAAT and Zfp161 putative binding sites. The human
TCOF1 upstream region also demonstrates an approximate
300 bpminimal promoter consisting of the conserved CCAAT
and ZF5 (the human homolog of Zfp161) sites that comple-
ments our result (Masotti et al., 2005). In addition, theminimal
promoter region encompasses a predicted CpG island that
remains unmethylated in P19 cells, E11.5 mouse embryo, and
adult mouse ear, thus contributing to constitutive expression.
FIG. 7. MethylScreen analysis. PCR product is shown at
252 bp for six different genomic DNA samples: untreated
P19 cell, HhaI methylated P19 cell, SssI methylated P19 cell,
untreated E11.5 mouse whole embryo, and two untreated
adult mouse ear punch samples. Genomic DNA was sub-
jected to each of four restriction digest reactions: (A) HhaI
methylation-sensitive restriction endonuclease, (B) McrBC
methylation-dependent restriction endonuclease, (C) both
HhaI and McrBC enzymes, and (D) glycerol only. Positive
control template (þ) for PCR is untreated P19 cell DNA not
subjected to restriction digestion, and negative control tem-
plate () for PCR is water only.
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Within the minimal promoter, the sequence surrounding
the putative CCAAT binding site is involved in cell-specific
activation of Tcof1, in that elimination of this region causes a
significant decrease in expression in P19 cells but not in
HEK293 cells (6B vs. 5B and 6A vs. 5A, Figs. 1B and 4A). Site-
directed mutation of the CCAAT site results in an expected
decrease in expression in P19 cells that also supports CCAAT
as an activation site (CCAAT*5B vs. 5B, Fig. 3). Previous mi-
croarray analyses identified the CCAAT binding factor Cebpz
(also known as Cebpa-rs1) as coordinately transcribed with
Tcof1 so that Cebpz is upregulated in Tcof1 overexpressing
and downregulated in Tcof1 knocked-down N1E-110 neuro-
blastoma cell lines, suggesting that Tcof1 and Cebpz are in-
volved in the same or similar pathways andmay be regulated
similarly (GEO accession no. GDS998; Mogass et al., 2004).
Cebpz is known to be expressed in mouse embryos and var-
ious adult tissues like Tcof1 (Hoeppner et al., 1996).
Interestingly, CCAAT-binding factors can participate in
coordinate tissue-specific regulation when the CCAAT ele-
ment is proximal to a c-myb regulatory element as in the Tcof1
upstream region, so that specific combinations of Cebp factors
interacting with c-myb could account for cell-specific differ-
ences in CCAAT-directed activation (Ramji and Foka, 2002).
In fact, Cebpb is shown in this study to associate with chro-
matin surrounding the c-myb candidate site; however, we
were unable to assess Cebpz binding because there was no
antibody available.
The c-myb element may be a tissue-specific
activator of Tcof1
Site-directed mutation of the c-myb site results in a de-
crease in expression in the HEK293 cell line, suggesting that
the c-myb site is an activator (c-myb*5B, Fig. 4B). However, c-
myb transcripts are not present in HEK293 cells, so it is likely
that a factor other than c-myb is responsible for this activity,
such as another myb factor (Ness, 2003).
Deletion of the 453 to 253 bp region surrounding the
conserved c-myb site demonstrates a repressor effect in P19
cells (5A vs. 4A, 5B vs. 4B in Fig. 1B); however, mutation of the
c-myb site shows no effect. So, the c-myb element itself is not
directly involved in repression in P19 cells, but another ele-
ment within the deleted region causes cell-specific repression.
For example, within this region in mouse and rat (but not
human, chimp, or rhesus macaque) is a stretch of thymidine
residues predicted to bind paired homeobox transcription
factor Pax1, a factor known to be involved in cartilage de-
velopment (Lefebvre and Smits, 2005). In human and chim-
panzee (but not rhesus macaque) there is a predicted YY1
binding site in the same position, and a polymorphism near
this YY1 binding site is associated with lower expression of
reporter gene in human cell culture (Masotti et al., 2005).
Furthermore, YY1 participates in neuroectoderm differentia-
tion to migratory neural crest cells through regulation of slug
in Xenopus (Morgan et al., 2004).
Unknown elements are general repressors
of Tcof1 expression
Deletion of the upstream region 829 to 453 bp that
contains the conserved Ik-1 predicted binding site shows P19
cell–specific repression in the 4A construct only (3A vs. 4A,
Fig. 1B). However, the Ik-1 transcript is absent from both cell
lines, so another cis- or trans-regulator in this region acts in a
cell-specific manner. Furthermore, the Ik-1 site was not tested
by site-directed mutation, so it is not known whether the
conserved site itself participates in repression but with a dif-
ferent binding factor.
Deletion of the upstream region 1751 to 942 bp shows
repression in both cell types, although there was no conserved
predicted binding site within this region. However, this de-
letion fragment does contain two of the peaks of conservation
at 1100 and 1700 bp, suggesting that these peaks may
contain novel cis-repressors upstream of the TSS. Further
study is required to identify specific cis- and trans-regulatory
elements that act in this region.
In conclusion, differential regulation of Tcof1 through re-
pression of constitutive activation appears to maintain a
tightly regulated level of Tcof1 in the early embryo that is
necessary for proper craniofacial development in the mouse,
as well as maintain low-level expression in other tissues.
Highly conserved sequences within the upstream region
contribute to maintenance of repression, while a 296 bp
fragment that includes highly conserved CCAAT and Zfp161
binding sites is responsible for high constitutive activation. So
then tissue-specific differences in expression of Tcof1 are a
result of lesser or greater repression governed through regions
upstream of the minimal promoter with tissue-specific effects.
While results in this study are primarily in vitro and limited to
two cell lines, we feel that these results will be the basis for
many future studies of Tcof1 regulation, including investi-
gating the basis of constitutive activation of the minimal
promoter in vivo.
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